Immunosuppressive therapy: Difference between revisions

From IDWiki
(: linkified, added more about ibrutinib)
Line 37: Line 37:
 
|}
 
|}
   
[[Category:Immunocompromised patients]]
+
[[Category:Immunocompromised hosts]]

Revision as of 22:36, 27 February 2020

Screening

Before starting immunosuppressive therapy, consider the following investigations:

  • Tuberculin skin test
  • Strongyloides serology, if from endemic country
  • Hep B and C serology
  • Cytomegalovirus serology
  • HIV serology

Management

  • Latent TB infection: start treatment at least 4 weeks prior to starting the biologic

Specific Medications

Medications Target Specific Risks
Eculizumab C5 complement Meningococcus (very high risk), needs MCV4 + MenB + pen prophylaxis
Rituximab CD20, on B cells Long-term B cell depletion
Natalizumab α4-integrin, on all leukocytes except neutrophils JC virus
Ibrutinib Bruton's tyrosine kinase (BTK), on B cells Invasive aspergillosis and other fungal infections